The clean sweep is a big win for Alnylam and the Sanofi-partnered RNAi drug, which is now set to be put before regulators at the end of the year.
Eric Carlson, Ph.D., has become the latest in a string of former Alcon employees to land at the smaller eye disease specialist.
For pharma and biotech, in which data is the most valuable asset, industry analysts agree that digital transformation presents an opportunity to realize…
Acceleron's collaboration with Celgene on sotatercept has taken another turn, giving Acceleron the right to develop the drug for pulmonary diseases.
Disarm Therapeutics has seen a strong $30 million series A round as it looks for a breakthrough approach in axonal degeneration.
Ultragenyx is putting up $138 million in cash to wrestle gene therapy biotech Dimension away from its first suitor.
Lefamulin held its own against established treatment moxifloxacin, raising hopes that Nabriva can establish it as a first-line treatment of CABP.
Rodin has gained $27 million as it plots clinical work on a new Alzheimer’s candidate next year.
In a phase 2 atopic dermatitis trial, Eli Lilly and Incyte's baricitinib hit its primary endpoint but missed a secondary objective.
The data monitoring committee ended the trial after ruling it would be futile to keep treating patients with the BMS-partnered Prostvac.
Sanofi and Lexicon aim to carve out a place for their experimental SGLT2/SGLT1 drug sotagliflozin in Type 1 diabetes.